FindTrial
Sign In

DOUBLE BLIND, RANDOMISED, PARALLEL GROUP, MULTICENTRE STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF CHF 1521 (FIXED COMBINATION OF MANIDIPINE AND DELAPRIL) VS LOSARTAN 50 MG AND HYDROCHLOROTHIAZIDE 12.5 MG IN TYPE 2 DIABETIC HYPERTENSIVE PATIENTS. The MORE study (Manidipine and delapril vs losartan and HCTZ in diabetic patients, 24 hour blood pressure).

DOUBLE BLIND, RANDOMISED, PARALLEL GROUP, MULTICENTRE STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF CHF 1521 (FIXED COMBINATION OF MANIDIPINE AND DELAPRIL) VS LOSARTAN 50 MG AND HYDROCHLOROTHIAZIDE 12.5 MG IN TYPE 2 DIABETIC HYPERTENSIVE PATIENTS. The MORE study (Manidipine and delapril vs losartan and HCTZ in diabetic patients, 24 hour blood pressure).

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001252-36-IT
Enrollment
Unknown
Registered
2004-09-16
Start date
2004-11-04
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild to moderate hypertension in type 2 diabetic patients MedDRA version: 6.1 Level: PT Classification code 10015488

Interventions

Trade Name: HIZAAR* 50/12,5 14 CPR Product Name: NA Product Code: NA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: IDROCLOROTIAZIDE (DC.IT) (FU) CAS Number: 58-93-5 Concentration unit:

Sponsors

CHIESI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Germany, Italy, Spain

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026